Patents
Literature
Patsnap Eureka AI that helps you search prior art, draft patents, and assess FTO risks, powered by patent and scientific literature data.

811 results about "Herpes virus" patented technology

Cellular reprogramming to reverse aging and promote organ and tissue regeneration

ActiveUS12274733B2Senses disorderNervous disorderTissue repairVaccine virus
Provided herein are engineered nucleic acids (e.g., expression vectors, including viral vectors, such as lentiviral vectors, adenoviral vectors, AAV vectors, herpes viral vectors, and retroviral vectors) that encode OCT4; KLF4; SOX2; or any combination thereof that are useful, for example, in inducing cellular reprogramming, tissue repair, tissue regeneration, organ regeneration, reversing aging, or any combination thereof. Also provided herein are recombinant viruses (e.g., lentiviruses, alphaviruses, vaccinia viruses, adenoviruses, herpes viruses, retroviruses, or AAVs) comprising the engineered nucleic acids (e.g., engineered nucleic acids), engineered cells, compositions comprising the engineered nucleic acids, the recombinant viruses, engineered cells, engineered proteins, chemical agents that are capable of activating expression of OCT4; KLF4; SOX2; or any combination thereof, an engineered protein selected from the group consisting of OCT4; KLF4; SOX2; or any combination thereof, an antibody capable of activating expression of OCT4; KLF4; SOX2; or any combination thereof, and methods of treating a (e.g., ocular disease), preventing a disease (e.g., ocular disease), regulating (e.g., inducing or inducing and then stopping) cellular reprogramming, regulating tissue repair, regulating tissue regeneration, or any combination thereof).
Owner:PRESIDENT & FELLOWS OF HARVARD COLLEGE

Method for improving crucian carp herpesvirus resistance of crucian carp

The invention relates to the technical field of fish genetic breeding, in particular to a method for improving carassius auratus gibelio resistance to carassius auratus gibelio herpesvirus. A CRISPR (clustered regularly interspaced short palindromic repeats) / Cas9 (CRISPR associated protein 9) gene editing technology is utilized to specifically knock out the carassius auratus gibelio irf10-B gene to obtain a mutant genotype individual of which three irf10-B alleles are terminated in advance, namely the required carassius auratus gibelio with high resistance The invention also discloses two specific knockout targets of the irf10-B gene and an allele sequence corresponding to a mutant genotype individual in which three alleles of the irf10-B are terminated in advance. According to the invention, the function of the irf10-B in the prussian carp is verified for the first time, a new germplasm of which the capability of resisting the herpesvirus of the prussian carp is improved by 30% is rapidly obtained by knocking out the single gene of the irf10-B, and the new germplasm has important industrial value.
Owner:INST OF AQUATIC LIFE ACAD SINICA

Cellular reprogramming to reverse aging and promote organ and tissue regeneration

Provided herein are engineered nucleic acids (e.g., expression vectors, including viral vectors, such as lentiviral vectors, adenoviral vectors, AV vectors, herpes viral vectors, and retroviral vectors) that encode OCT4; KLF4; SOX2; or any combination thereof that are useful, for example, in inducing cellular reprogramming, tissue repair, tissue regeneration, organ regeneration, reversing aging, or any combination thereof. Also provided herein are recombinant viruses (e.g., lentiviruses, alphaviruses, vaccinia viruses, adenoviruses, herpes viruses, retroviruses, or AAVs) comprising the engineered nucleic acids (e.g., engineered nucleic acids), engineered cells, compositions comprising the engineered nucleic acids, the recombinant viruses, engineered cells, engineered proteins, chemical agents that are capable of activating expression of OCT4; KLF4; SOX2; or any combination thereof, an engineered protein selected from the group consisting of OCT4; KLF4; SOX2; or any combination thereof, an antibody capable of activating expression of OCT4; KLF4; SOX2; or any combination thereof, and methods of treating a (e.g., ocular disease), preventing a disease (e.g., ocular disease), regulating (e.g., inducing or inducing and then stopping) cellular reprogramming, regulating tissue repair, regulating tissue regeneration, or any combination thereof).
Owner:PRESIDENT & FELLOWS OF HARVARD COLLEGE

Application of lactic acid in prevention and treatment of aquatic virus infection

The invention discloses an application of lactic acid (Lactate) in prevention and treatment of infection of CyHV-2 (Cyprinid Herpesvirus, CyHV-2), SVCV (Spring Viraemia of Carp Virus) and GCRV (Grass Carp Reovirus), a result of a cell line infection model shows that the lactic acid has a significant protection effect on cells infected by CyHV-2, SVCV and GCRV, and the lactic acid has a significant protection effect on cells infected by CyHV-2, SVCV and GCRV. Furthermore, a molecular biology experiment result shows that the transcription level of the virus related genes treated by lactic acid is obviously inhibited. Therefore, the lactic acid can be used as a medicine or an additive for preventing and treating CyHV-2, SVCV and GCRV infection, and has the advantages of low dosage and good protection effect.
Owner:INST OF AQUATIC LIFE ACAD SINICA

Reagent and method for detecting berberine-resistant virus

The invention discloses a reagent and a method for detecting berberine-resistant viruses. The reagent provided by the invention comprises an antibody or an antigen binding fragment thereof, the antibody or the antigen binding fragment thereof comprises a heavy chain complementarity determining region HCDR1-3 and / or a light chain complementarity determining region LCDR1-3, the heavy chain complementarity determining region HCDR1-3 has a sequence as shown in SEQ ID NO.5-7, and the light chain complementarity determining region LCDR1-3 has a sequence as shown in SEQ ID NO.8-10. The reagent can be used for detecting the berberine-resistant herpes simplex virus type 1, so that the treatment effect can be evaluated in advance before berberine is applied for treatment.
Owner:北京市延庆区疾病预防控制中心(北京市延庆区卫生健康监督所) +1

Construction method and application of recombinant herpesvirus turkey for co-expressing NDV F gene and H9 subtype AIV HA gene

The invention provides a construction method and application of a recombinant herpesvirus turkey for co-expressing an NDV (Newcastle Disease Virus) F gene and an H9 subtype AIV (Avian Influenza Virus) HA gene, and belongs to the field of genetic engineering vaccines. The recombinant clone technology is utilized, an expression framework containing a Newcastle disease virus gene VII type strain F gene and an H9 subtype avian influenza virus HA gene is inserted between 95322-95323 nucleotides or between 112071-112088 nucleotides of a turkey herpesvirus FC126 strain, and the recombinant clone with the F gene and HA gene expression framework inserted into a turkey herpesvirus genome is constructed and obtained. Recombinant turkey herpesvirus vaccine strains H20901 and H20902 for co-expressing the Newcastle disease virus F gene and the H9 subtype avian influenza virus HA gene are rescued and obtained by the recombinant turkey herpesvirus vaccine strain H20901 and H20902. The vaccine prepared from the recombinant turkey herpesvirus provided by the invention can provide dual protection for the Newcastle disease virus and the avian influenza virus, and has a good market application prospect.
Owner:INST OF URBAN AGRI CHINESE ACADEMY OF AGRI SCI +1

Recombinant turkey herpesvirus co-expressing avian influenza H9 gene and fowl adenovirus 4 type Fiber-2 gene and application of recombinant turkey herpesvirus

ActiveCN119639689AGood immune effectMeets candidate strain requirementsMicroorganism based processesAntiviralsTGE VACCINETurkey poult
The invention belongs to the technical field of biology, and discloses a recombinant turkey herpesvirus co-expressing an avian influenza H9 gene and an avian adenovirus 4 type Fiber-2 gene, the H9 gene containing a promoter and a terminator is inserted between an HVT053 site and an HVT054 site of the turkey herpesvirus, the Fiber-2 gene containing a promoter and a terminator is inserted between an HVT087 site and an HVT088 site of the turkey herpesvirus, and the recombinant turkey herpesvirus co-expressing the avian influenza H9 gene and the avian adenovirus 4 type Fiber-2 gene is obtained. The recombinant virus is obtained. The recombinant turkey herpesvirus can stably co-express the H9N2 subtype avian influenza virus H9 protein and the fowl adenovirus 4 type Fiber-2 protein, has very excellent immune performance, and effectively improves the immune effect of the recombinant virus of the traditional fowl adenovirus Fiber-2 gene; compared with the recombinant herpesvirus of turkey which singly expresses any one of the H9N2 subtype avian influenza virus H9 protein and the fowl adenovirus 4 type Fiber-2 protein, the recombinant herpesvirus of turkey has the advantage that the performance of the recombinant herpesvirus of turkey is not weakened. Meanwhile, the invention also provides application and a vaccine of the recombinant herpesvirus of turkeys.
Owner:CHINA AGRI UNIV

Cellular reprogramming to reverse aging and promote organ and tissue regeneration

Provided herein are engineered nucleic acids (e.g., expression vectors, including viral vectors, such as lentiviral vectors, adenoviral vectors, AAV vectors, herpes viral vectors, and retroviral vectors) that encode OCT4; KLF4; SOX2; or any combination thereof that are useful, for example, in inducing cellular reprogramming, tissue repair, tissue regeneration, organ regeneration, reversing aging, or any combination thereof. Also provided herein are recombinant viruses (e.g., lentiviruses, alphaviruses, vaccinia viruses, adenoviruses, herpes viruses, retroviruses, or AAVs) comprising the engineered nucleic acids (e.g., engineered nucleic acids), engineered cells, compositions comprising the engineered nucleic acids, the recombinant viruses, engineered cells, engineered proteins, chemical agents that are capable of activating expression of OCT4; KLF4; SOX2; or any combination thereof, an engineered protein selected from the group consisting of OCT4; KLF4; SOX2; or any combination thereof, an antibody capable of activating expression of OCT4; KLF4; SOX2; or any combination thereof, and methods of treating a (e.g., ocular disease), preventing a disease (e.g., ocular disease), regulating (e.g., inducing or inducing and then stopping) cellular reprogramming, regulating tissue repair, regulating tissue regeneration, or any combination thereof).
Owner:PRESIDENT & FELLOWS OF HARVARD COLLEGE

Adenoviral vectors encoding hepatitis b viral antigens fused to herpes virus glycoprotein d and methods of using the same

Provided herein are non-naturally occurring variants of the hepatitis B virus (HBV) Core protein, the HBV polymerase N-terminal domain, and the HBV polymerase C-terminal domain, as well as immunogenic fragments thereof. Fusion proteins comprising the HBV variants fused to a herpes simplex virus (HSV) glycoprotein (gD) sequence, as well as methods of using the fusion proteins, are also provided.
Owner:WISTAR INSTITUTE +1

Novel three-antigen HSV-2 adjuvant subunit vaccine as well as preparation method and application thereof

The invention provides a novel three-antigen HSV-2 adjuvant subunit vaccine as well as a preparation method and application thereof. The vaccine comprises herpes simplex virus recombinant protein and a composite adjuvant, the herpes simplex virus recombinant protein comprises extracellular domains of three proteins, namely HSV-2gE, gD and gC, wherein the amino acid sequences of the extracellular domains of the HSV-2gE, the gD and the gC are respectively shown as SEQ ID NO.1, SEQ ID NO.2 and SEQ ID NO.3; and the composite adjuvant is composed of CpG oligodeoxynucleotide and QS-21. Experiments prove that by adding the composite adjuvant composed of CpG oligodeoxynucleotide and QS-21, the immunogenicity, in-vivo protectiveness, virus removal and other immune functions of the HSV-2 subunit vaccine can be remarkably improved; meanwhile, the vaccine is a cross immune protection vaccine of an HSV-2 virus strain and an HSV-1 virus strain.
Owner:INST OF MEDICAL BIOLOGY CHINESE ACAD OF MEDICAL SCI

Kit and method for simultaneously detecting 11 pathogens of urogenital system and application

PendingCN119530410Ashort healing timereduce workloadMicrobiological testing/measurementMicroorganism based processesUreaplasma urealyticum+Ureaplasma parvumTrichomonas vaginalis
The invention provides a kit and a method for simultaneously detecting 11 pathogens of a urogenital system and application, and belongs to the field of molecular biology. The primer group is used for detecting urogenital tract pathogens, and the urogenital tract pathogens comprise ureaplasma urealyticum (UU), chlamydia trachomatis (CT), mycoplasma genitalium (MG), ureaplasma parvum (UP), mycoplasma hominis (MH), adenovirus (ADV), trichomonas vaginalis (TV), herpes simplex virus type I (HSV-I), herpes simplex virus type II (HSV-II), haemophilus influenzae (HI) and neisseria gonorrhoeae (NG). The primer group is used for multi-joint detection of non-gonococcal urethritis related pathogens, has high specificity and sensitivity, is adaptive to non-invasive urine specimens, and supports home self-sampling. The kit is used for clinical diagnosis and can quickly judge pathogen types. Precise medication is performed based on a detection result, the healing time of a patient is shortened, the burden of a doctor is relieved, and meanwhile the pathogen transmission risk is reduced.
Owner:CUI ZHEN BIOTECHNOLOGY CO LTD (ZHENG ZHOU)

Pharmaceutical compositions for herpes virus

The present invention relates to methods and compositions for treating and / or inhibiting the development or progression of diseases or disorders caused by, or associated with, herpes virus infection. In particular, provided are long-acting injectable depot pharmaceutical compositions comprising Compound 1 or a pharmaceutically acceptable salt thereof; methods for their manufacture; and the use of said pharmaceutical compositions as a medicament and for the treatment of diseases or disorders caused by, or associated with, herpes virus.
Owner:ASSEMBLY BIOSCIENCES INC +1

Reversing aging of the central nervous system

Provided herein are engineered nucleic acids (e.g., expression vectors, including viral vectors, such as lentiviral vectors, adenoviral vectors, AAV vectors, herpes viral vectors, and retroviral vectors) that encode OCT4; KLF4; SOX2; or any combination thereof that are useful, for example, in inducing cellular reprogramming, tissue repair, tissue regeneration, organ regeneration, reversing aging, or any combination thereof in the central nervous system or ex vivo. Also provided herein are recombinant viruses (e.g., lentiviruses, alphaviruses, vaccinia viruses, adenoviruses, herpes viruses, retroviruses, or AAVs) comprising the engineered nucleic acids (e.g., engineered nucleic acids), engineered cells, compositions comprising the engineered nucleic acids, the recombinant viruses, engineered cells, engineered proteins, chemical agents that are capable of activating expression of OCT4; KLF4; SOX2; or any combination thereof, an engineered protein selected from the group consisting of OCT4; KLF4; SOX2; or any combination thereof, an antibody capable of activating expression of OCT4; KLF4; SOX2; or any combination thereof, and methods of treating a disease (e.g., a neurological disease), preventing a disease (e.g., neurological disease), regulating (e.g., inducing or inducing and then stopping) cellular reprogramming, regulating tissue repair, regulating tissue regeneration, or any combination thereof.
Owner:PRESIDENT & FELLOWS OF HARVARD COLLEGE

RNA compositions encoding herpes simplex virus glycoprotein b antigens and uses thereof

The present disclosure provides a polyribonucleotide encoding a polypeptide that comprises a viral antigen from Herpes Simplex Virus-2 (HSV-2); for example, the viral antigen comprises the ectodomain of HSV-2 glycoprotein B. The polyribonucleotide can be formulated as an RNA composition useful for inducing anti-HSV immune responses in a subject.
Owner:THE TRUSTEES OF THE UNIV OF PENNSYLVANIA +1

Pyridone endoperoxide with antibacterial and antiviral activity and application thereof

The invention discloses pyridone endoperoxide with antibacterial and antiviral activity and application thereof, and belongs to the fields of organic compound synthesis and medical technology, food engineering and the like. The invention proves that the series of endoperoxides can effectively kill pathogenic bacteria, fungi and viruses, including propionibacterium acnes, escherichia coli, staphylococcus aureus, candida albicans, human papilloma viruses, herpes simplex viruses and the like. The internal peroxide designed by the invention has the capability of treating skin diseases, is expected to be developed into a first-line medicine for treating skin diseases caused by pathogen invasion, and mainly relates to bacterial skin diseases, fungal skin diseases and viral skin diseases caused by pathogen infection. Meanwhile, the series of endoperoxides can be used for treating oral infection, periodontitis, infection of shoulder and other joint operations, and bacterial infection such as pressure sores. In addition, the peroxides in the series can also be used in the fields of food preservation, disinfectant preparation and the like.
Owner:DALIAN UNIV OF TECH

RT-PCR (Reverse Transcription-Polymerase Chain Reaction) kit for simultaneously detecting multiple human herpes viruses and use method thereof

The invention belongs to the technical field of molecular biology, and particularly relates to an RT-PCR kit for simultaneously detecting multiple human herpes viruses and a using method thereof.The kit comprises RT-PCR primer probes, a buffer solution and Taq enzyme, the primer probes and the buffer solution are fully premixed for loading the Taq enzyme, and the primer probes and the buffer solution are mixed for loading the Taq enzyme. The primer probes comprise forward and reverse amplification primers and detection probes respectively aiming at the human herpes virus type 5, the human herpes virus type 6, the human herpes virus type 7 and the human herpes virus type 8, and the sequences are respectively shown as SEQ ID NO.1-SEQ ID NO.13. The kit disclosed by the invention can be used for rapidly detecting and identifying the four types of human herpes viruses at the same time; the kit has high accuracy, specificity and sensitivity.
Owner:JIANGSU UNINOVO BIOLOGICAL TECH

Quadruple egg yolk antibody for cats as well as preparation method and application of quadruple egg yolk antibody

The invention relates to the technical field of antibodies, in particular to a quadruple egg yolk antibody for cats as well as a preparation method and application of the quadruple egg yolk antibody. The quadruple egg yolk antibody for cats, provided by the invention, comprises egg yolk antibodies aiming at four viruses, namely cat parvovirus, cat herpes virus type I, cat calicivirus and cat coronavirus, can specifically neutralize the viruses, has relatively high neutralizing antibody titer, and can be used for preventing and treating infection of the viruses and diseases caused by the infection. The quadruple egg yolk antibody for cats provided by the invention has the advantages that the preparation method is simple and efficient, the egg yolk antibody is high in yield and purity, the prepared antibody is high in titer and low in cost, large-scale production is easy to realize and the like, and the quadruple egg yolk antibody has a wide application prospect.
Owner:BEIJING KATE DOUG BIOTECHNOLOGY CO LTD

Engineered herpes simplex virus vectors and uses thereof

The invention discloses an HSV-1 replication-deficient recombinant virus vector and an application of the HSV-1 replication-deficient recombinant virus vector. Specifically, the method comprises the following steps: performing gene editing on a specific genome segment in an HSV-1 genome to obtain an HSV-1 replication-defective recombinant virus vector; wherein compared with the existing HSV-1 replication-deficient recombinant virus vector, the HSV-1 replication-deficient recombinant virus vector can express an exogenous gene more efficiently, and the HSV-1 replication-deficient recombinant virus vector, as an excellent delivery vector, can effectively deliver the exogenous gene into the body of a subject to achieve a treatment effect.
Owner:BEIJING WELLGENE CO LTD

Vaccine for preventing feline herpesvirus infection, and preparation method therefor and use thereof

PCT designated stage expiredWO2025011592A1Antibody mimetics/scaffoldsVirus peptidesDosing regimenAntigen
Provided are a vaccine for preventing feline herpesvirus infection, and a preparation method therefor and the use thereof. By means of antigen sequence design and screening, an antigen peptide and an mRNA nucleic acid molecule having excellent expression effects are obtained, and thus a vaccine prepared therefrom has a good immune effect and can induce the production of a highly-effective and durable level neutralizing antibody against a feline herpesvirus at a very low dose and dosing regimen; meanwhile, the mRNA vaccine has the characteristics of a good stability, a high delivery efficiency, safety, effectiveness and a controllable quality.
Owner:CANSINO (SHANGHAI) BIOLOGICAL RES CO LTD

A crystalline form of 2-(3-(2,,5'-difluoro-[1,1'-biphenyl]-4-YL)-2-oxotetrahydropyrimidin-1(2H)-YL)-4-methylthiazole-5-sulfonamide

The invention relates to a novel crystalline form of a helicase-primase inhibitor compound, as well as to pharmaceutical compositions comprising the same, methods for its production, the use of the crystalline form in a medicament and for the treatment of herpes virus infections.
Owner:ASSEMBLY BIOSCIENCES INC

A crystalline form of 2-(3-(2,,5'-difluoro-[1,1'-biphenyl]-4-YL)-2-oxotetrahydropyrimidin-1(2H)-YL)-4-methylthiazole-5-sulfonamide

The invention relates to a novel crystalline form of a helicase-primase inhibitor compound, as well as to pharmaceutical compositions comprising the same, methods for its production, the use of the crystalline form in a medicament and for the treatment of herpes virus infections.
Owner:ASSEMBLY BIOSCIENCES INC

Novel helper plasmid for producing recombinant adeno-associated virus as well as construction method and application of novel helper plasmid

The invention discloses a novel helper plasmid for producing a recombinant adeno-associated virus as well as a construction method and application of the novel helper plasmid. The novel helper plasmid is constructed by inserting a UL12 element of an I-type herpes simplex virus HSV-1 and an NS2 element of a human bola virus HBoV into a basic pHelper plasmid, the constructed novel helper plasmid UL12-NS2-pHelper can remarkably improve the titer of rAAV produced by HEK293 cells, the proportion of solid rAAV is increased, immunoreaction and toxicity caused by empty capsid can be reduced, and the helper plasmid can be used for preparing the rAAV. The treatment dosage is reduced, and the curative effect and safety are improved.
Owner:JIANGNAN UNIV

RNA vaccines encoding herpes simplex virus glycoproteins and uses thereof

PCT designated stage expiredWO2024249967A1Viral antigen ingredientsVirus peptidesRecurrent genital herpesTGE VACCINE
The present disclosure provides compositions for the prevention and treatment of genital herpes, comprising nucleoside modified RNAs that encode herpes simplex virus (HSV) glycoproteins, including those involved in virus entry and immune evasion, and methods of use thereof.
Owner:THE TRUSTEES OF THE UNIV OF PENNSYLVANIA +1

Mouse anti-porcine herpesvirus type 1 gE monoclonal antibody, immunogen and application thereof

The invention relates to the technical field related to immunological detection, in particular to a mouse anti-porcine herpesvirus type 1 gE monoclonal antibody as well as an immunogen and application of the mouse anti-porcine herpesvirus type 1 gE monoclonal antibody. The amino acid sequences of complementary determining regions CDR1, CDR2 and CDR3 of a heavy chain variable region of the monoclonal antibody or the antigen binding fragment of the monoclonal antibody are respectively as follows: GFSLSTSGMG, IVWGSETGRVTISRDNSK and VRYYDGDDD, and the amino acid sequences of complementary determining regions CDR1, CDR2 and CDR3 of a light chain variable region of the monoclonal antibody or the antigen binding fragment of the monoclonal antibody are respectively as follows: KSSQSLLYSDGKTFLN, LGSNRAS and SSLPHED. The monoclonal antibody can be specifically combined with gE proteins of all subtypes of the porcine herpesvirus type 1, and a porcine herpesvirus type 1 detection kit prepared from the monoclonal antibody has the advantages of high sensitivity, strong specificity, wide detection range, short detection time and the like.
Owner:BEIJING ANIMAL DISEASE PREVENTION & CONTROL CENT +1

Compositions comprising lopinavir and treatment of conditions

Provided herein are methods and compositions for treating and / or inhibiting the development or progression of conditions caused by, or associated with, Herpes Simplex Virus (HSV) infection. In particular, provided are compositions comprising lopinavir alone, or lopinavir and ritonavir, methods for their manufacture; and the use of said pharmaceutical compositions as a medicament. In particular, pharmaceutical compositions are provided for use in treating and / or inhibiting the progression of HSV related conditions.
Owner:DOUGLAS PHARMA

A biomarker for predicting the efficacy of oncolytic virus in the treatment of malignant tumors and its application

The present invention discloses a biomarker for predicting the efficacy of oncolytic virus in treating malignant tumors and its application. The biomarker includes SH3BP2, the oncolytic virus is oncolytic herpes simplex virus, and the malignant tumor is glioma. Before treating malignant glioma with oncolytic virus, the expression level of SH3BP2 in tumor tissues before treatment is detected to predict the therapeutic effect of oncolytic virus on malignant glioma.
Owner:BEIJING NEUROSURGICAL INST

Purine compound as well as preparation method and application thereof

The invention relates to the field of medicinal chemistry, and particularly discloses purine compounds as well as a preparation method and application thereof. The purine compound provided by the invention is a compound as shown in a formula (I) or pharmaceutically acceptable salt thereof: # imgabs0 #. The purine compound disclosed by the invention is designed based on a novel purine skeleton structure, and the anti-herpes simplex virus type 1 (HSV-1) activity of the purine compound is verified through an in-vitro antiviral experiment. Experimental data show that the HSV-1 median inhibitory concentration (EC50) of the series of compounds to HSV-1 is obviously superior to that of a clinical first-line drug acyclovir, and the series of compounds show better virus inhibition efficiency on the premise of keeping a similar selectivity index (SI = CC50 / EC50). The technical scheme breaks through the molecular framework limitation of the existing anti-HSV-1 drugs (such as acyclovir, famciclovir and the like), and has good clinical transformation value.
Owner:ZHENGZHOU UNIV

Application of fructose-1, 6-diphosphate in preparation of medicine for preventing and treating herpes simplex virus type 1 infection

The invention belongs to the field of medicines, and particularly relates to application of fructose-1, 6-diphosphate in preparation of a medicine for preventing and treating herpes simplex virus type 1 infection. The fructose-1, 6-diphosphate (FBP) can be used for inhibiting replication of RNA (Ribonucleic Acid) and DNA (Deoxyribose Nucleic Acid) viruses in vitro and in vivo. Experiments show that the inhibition effect does not depend on I-type interferon-mediated innate immunity to a great extent, but occurs through HMGB1 (High Mobility Group Box 1). After virus infection, FBP reduces the protein level of HMGB1 by promoting lysosome degradation of HMGB1. In addition, the FBP can directly inhibit the combination of the HMGB1 and the viral genome, so that the virus replication is inhibited. The key effect of FBP in inhibition of virus replication is highlighted through research, and a potential target spot for controlling virus infection is provided.
Owner:SICHUAN ACADEMY OF MEDICAL SCI SICHUAN PROVINCIAL PEOPLES HOSPITAL

Compositions and methods for preventing or ameliorating neonatal HSV infection

ActiveUS12378305B2Nervous disorderViral antigen ingredientsHerpes simplex viral infectionVirology
The present disclosure relates to compositions and methods for treating or preventing neonatal herpes simplex virus (HSV) infection and / or the neurological and / or non-neurological sequelae thereof.
Owner:TRUSTEES OF DARTMOUTH COLLEGE THE +1

Composition and kit for detecting cat stomatitis pathogens and application of composition and kit

The invention belongs to the field of molecular biological detection, and particularly relates to a composition and a method for joint detection and distinguishing of feline calicivirus, feline herpes virus, feline leukemia virus and feline human immunodeficiency virus, and application of the composition and the method. According to the combined detection composition provided by the invention, four targets can be simultaneously detected in one-time sample detection through a multiple fluorescent RPA detection technology, the on-machine detection process can be completed within 30 minutes, and the detection method has the characteristics of high flux, short time and low cost. The invention greatly solves the problems of difficult and pain points in the industries of long time, low sensitivity, poor specificity and the like in the current cat stomatitis pathogen identification, improves the accurate and rapid detection of cat stomatitis diseases, and provides a simple and efficient detection reagent and method for scientific research and clinical detection of suspected cat stomatitis diseases.
Owner:HUNAN SHENGWEI ANIMAL HUSBANDRY BIOTECHNOLOGY DEV CO LTD